Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors

Choosing Healthcare ETFs: IHE's Advantage Over IBB for Many Investors

<iShares U.S. Pharmaceuticals ETF (IHE) +0.98%> and <iShares Biotechnology ETF (IBB) +1.73%> are two distinct funds targeting different segments of the domestic healthcare market. IHE concentrates on established drugmakers, while IBB offers broader exposure to higher-volatility biotechnology research and development companies. This article explores how their differing strategies and risk profiles could influence a diversified portfolio.

The 1-year return, representing total return over the trailing 12 months, is 79% for IHE and 38% for IBB. Both funds provide dividend yields, with IHE yielding 1.4% and IBB at 0.2%. This significant difference in dividend potential could make IHE more attractive to income-focused investors.

Expense ratios are another crucial factor to consider. IHE boasts a lower expense ratio of 0.37%, compared to IBB's 0.44%. This cost advantage can lead to higher net returns for investors, particularly when factoring in the additional dividend income from IHE.

IHE's holdings consist of 53 pharmaceutical stocks, making it a highly concentrated fund. Its largest positions include Eli Lilly (LLY), Johnson & Johnson (JNJ), and Zoetis. In contrast, IBB holds 243 stocks, with a more diversified portfolio that includes biotechnology, life sciences tools, and pharmaceuticals. Its top holdings are Gilead Sciences (GILD), Amgen (AMGN), and Vertex Pharmaceuticals (VRTX).

Ultimately, investors should weigh these factors based on their individual goals and risk tolerance. IHE's lower costs, higher returns, and income potential may make it the preferred choice for many investors. However, those seeking broader exposure to the biotechnology sector might still find value in IBB. As with any investment decision, thorough research and consideration of personal financial objectives are essential.